Idorsia Ltd. · SIX:IDIA

Idorsia — FY2017 Earnings Presentation

22 slides from Idorsia's earnings presentation, Feb 6, 2018

  1. Slide 1: Idorsia – Reaching out for more

    Slide 1: Idorsia – Reaching out for more

    Idorsia – Reaching out for more Idorsia - Investor Webcast - 6 February 2018

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,

  3. Slide 3: More novel drugs – Inspiring potential

    Slide 3: More novel drugs – Inspiring potential

    More novel drugs – Inspiring potential Jean-Paul Clozel, CEO

  4. Slide 4: Highlights in 2017

    Slide 4: Highlights in 2017

    Highlights in 2017 Pipeline Results Substantial progress with the pipeline – productive discussions with health authorities Idorsia is born Idorsia created and listed – pipeline advanced without missing a beat Partnerships Development partnership with Janssen Biotech to advance aprocitentan Research

  5. Slide 5: Idorsia Today

    Slide 5: Idorsia Today

    Idorsia Today >650 Highly qualified 11 professionals Compounds in the pipeline, with four progressing to late-stage development in the year ahead >1 bn Swiss francs in cash > 550 State-of-the-art laboratory workspaces 5 Full Year Financial Reporting

  6. Slide 6: Our Strategic Priorities

    Slide 6: Our Strategic Priorities

    Our Strategic Priorities 1 Deliver at least three products to market 5 key priorities to ensure the company’s success 2 Build a commercial organization over the next 5 years 3 Bring Idorsia to profitability in a sustainable manner 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize

  7. Slide 7: More in the pipeline – Promising compounds

    Slide 7: More in the pipeline – Promising compounds

    More in the pipeline – Resistant hypertension Fabry disease Promising compounds Management Aprocitentan Lucerastat Glucosylceramide synthase inhibitor Vasospasm associated with aneurysmal Dual endothelin Status: Advancing to subarachnoid Diversified and balanced pipeline: CNS, receptor antagonist Ph

  8. Slide 8: More in the pipeline – Promising compounds

    Slide 8: More in the pipeline – Promising compounds

    More in the pipeline – Resistant hypertension Fabry disease Promising compounds Management Aprocitentan Lucerastat Glucosylceramide synthase inhibitor Vasospasm associated with aneurysmal Dual endothelin Status: Advancing to subarachnoid Diversified and balanced pipeline: CNS, receptor antagonist Ph

  9. Slide 9: Lucerastat for Fabry disease

    Slide 9: Lucerastat for Fabry disease

    Lucerastat for Fabry disease • Fabry disease is a rare genetic disorder involving deficiency or Fabry disease dysfunction of an enzyme that breaks down fatty waste products Compound: Lucerastat in body • Lucerastat oral monotherapy offering new treatment approach Mechanism of action: with potential

  10. Slide 10: ACT-541469 for insomnia

    Slide 10: ACT-541469 for insomnia

    ACT-541469 for insomnia • Potential for fast onset of sleep and duration of action not Insomnia exceeding a normal night, while maintaining natural sleep Compound: ACT-541468 architecture • Phase 3 program consisting of three studies to evaluate time to Mechanism of action: sleep onset and duration

  11. Slide 11: Aprocitentan for resistant hypertension management

    Slide 11: Aprocitentan for resistant hypertension management

    Aprocitentan for resistant hypertension management • Aprocitentan has great potential in resistant hypertension Resistant hypertension management as an oral, once daily treatment with potent, long management lasting hypertensive effects Compound: Aprocitentan • In collaboration with Janssen Biotech

  12. Slide 12: Clazosentan for cerebral vasospasm associated with aSAH

    Slide 12: Clazosentan for cerebral vasospasm associated with aSAH

    Clazosentan for cerebral vasospasm associated with aSAH* • Developed as intravenous infusion for prevention and treatment Cerebral vasospasm of cerebral vasopasms in patients who have suffered an aSAH Compound: Clazosentan • Has potential to prevent ischemic complications of cerebral vasoconstrictio

  13. Slide 13: More in the pipeline – Promising compounds

    Slide 13: More in the pipeline – Promising compounds

    More in the pipeline – Promising compounds Diversified and balanced pipeline: CNS, cardiovascular and immunological disorders & orphan diseases Systemic lupus Duchenne muscular erythematosus dystrophy Cenerimod Vamorolone S1P1 receptor Dissociative steroid modulator Status: Phase 2 Acute Coronary St

  14. Slide 14: More energy – Growing and delivering

    Slide 14: More energy – Growing and delivering

    More energy – Growing and delivering André Muller, CFO

  15. Slide 15: Operating results

    Slide 15: Operating results

    Operating results -48 Non-GAAP US-GAAP 158 -75 -27 8 -10 -6 -8 Revenues Research Development G&A Non-GAAP D&A SBC US-GAAP Operating Operating results results Financial results as of Dec 31, 2017 15 Full Year Financial Reporting

  16. Slide 16: Net results

    Slide 16: Net results

    Net results Non-GAAP US-GAAP 8 5 -8 -14 -3 -7 Operating results Financial Income Tax Non-Controlling Net results results results Interests Financial results as of Dec 31, 2017 16 Full Year Financial Reporting

  17. Slide 17: Cash flow

    Slide 17: Cash flow

    Cash flow 14 227 -150 1'091 1'000 Cash @ OPEX J&J Capex Liquidity @ Demerger (excl. milestone) milestone & WCR Dec 31, 2017 Financial results as of Dec 31, 2017 17 Full Year Financial Reporting

  18. Slide 18: Liquidity

    Slide 18: Liquidity

    Liquidity 1’091 250 218 Cash deposits long-term Cash deposits 1'000 short-term Cash and 622 Cash Equivalents Liquidity @ Liquidity @ Demerger Dec 31, 2017 Financial results as of Dec 31, 2017 18 Full Year Financial Reporting

  19. Slide 19: Convertible bond

    Slide 19: Convertible bond

    Convertible bond 580 84 445 445 84 80 Equity component 496 361 365 Debt component CB @ CB post conversion of CB @ Demerger 1st tranche Dec 31, 2017 Financial results as of Dec 31, 2017 19 Full Year Financial Reporting

  20. Slide 20: Potential issued shares

    Slide 20: Potential issued shares

    Potential issued shares 157.8 162.6 4.8 38.7 Equity instruments 50.5 Equity derivatives Issued common 119.1 shares 107.3 Potential shares @ Potential shares @ Demerger Dec 31, 2017 Financial results as of Dec 31, 2017 20 Full Year Financial Reporting

  21. Slide 21: Financial Guidance

    Slide 21: Financial Guidance

    Financial Guidance 2018 Unforeseen events and potential milestone expenses excluded, we expect non-GAAP operating expenses for 2018 to be around 390 million Swiss francs, mainly depending on when each of the different Phase 3 programs commences 21 Full Year Financial Reporting

  22. Slide 22: Be prepared for more

    Slide 22: Be prepared for more

    Be prepared for more 22 Full Year Financial Reporting

Source: Internet Archive copy of idorsia.com

More decks from Idorsia Ltd.

All 55 Idorsia decks